Mesoblast Ltd. (MESO), which is developing off-the-shelf cellular medicines for life-threatening inflammatory conditions, is planning to file a Biologics License Application for Ryoncil with the FDA next week.
Ryoncil is being developed for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). It comprises of culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor.
Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) is one of the significant complications that can arise following allogeneic hematopoietic cell transplantation.
MESO has traded in a range of $1.61 to $10.24 in the last 1 year. The stock closed Friday's trading (June 28, 2024) at $6.81, down 0.58%.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.